Skip to content
DraconiticResearch
Search Sources API
181,713 studies31 sourcesUpdated 54 min ago
Peer-reviewedCC BYClinical case reports

Improvement of Erectile Function After Switching From Valsartan to Olmesartan Within a Fixed‐Dose Antihypertensive Combination: A Case Report

  • Mario Ćurković1
  • Nika Ćurković2
  1. 1Osijek ‐ Baranja County Health Center
  2. 2Health Center Zagreb‐Center
Read full textPDFDOICite

Abstract

Intra‐class differences may exist between ARBs regarding tissue‐specific outcomes. In this case, valsartan was probably associated with erectile dysfunction (Naranjo score 7). Switching to olmesartan was followed by resolutions of symptoms. An intra‐class switch may be considered in selected patients with suspected drug‐associated erectile dysfunction after evaluating other vascular, metabolic, or lifestyle contributions. Clinicians should remain cautious, as concurrent treatment modifications can confound definitive causal attributions.

Related

  1. Evaluating the efficacy of commercial Sela tea- high blood and Sela tea-blood sugar in combination with antihypertensive and anti-diabetic drugs: an in vitro study
    Motlalepula Gilbert Matsabisa, Sthabiso Iminathi Mthethwa, Nqobile Vanessa Hadebe +2
    Clinical PhytosciencePeer-reviewedCC BYFull textEndocrinology & metabolismDOAJ
  2. Olmesartan-associated enteropathy presenting as severe malnutrition
    Alinafe Mpanda, Mariame Sylla, Eric D Young
    BMJ Case ReportsPeer-reviewedCC BY-NC 4.0Full textGeneral medicinePMC
  3. Clinical outcomes of sacubitril/valsartan in patients with mildly reduced or preserved ejection fraction and acute heart failure: a multi-institutional study
    Birdie Huang, Chun-Chi Chen, Ming-Lung Tsai +8
    Annals of medicinePeer-reviewedCC BY-NCFull textGeneral medicineEurope PMC
  4. Mechanisms and clinical outcomes of sacubitril-valsartan and SGLT2 inhibitors in heart failure patients: a retrospective cohort study
    Xuzheng Zhong, Lei Xia, Li Li +1
    Frontiers in Cardiovascular MedicinePeer-reviewedCC BY 4.0Full textCardiovascular medicineCrossrefEurope PMC
  5. PATIENT PROFILING AND OUTCOME OF ANTIHYPERTENSIVE TREATMENT. An Exploratory Analysis of the VALUE Trial.
    P. W. de Leeuw, C. L. Söraas, G. Mancia +5
    medRxivPreprintAll rights reservedFull textCardiovascular medicinemedRxiv

Cite

BibTeXRIS
BibTeX
@article{curkovic2026improvement,
  title = {{Improvement of Erectile Function After Switching From Valsartan to Olmesartan Within a Fixed‐Dose Antihypertensive Combination: A Case Report}},
  author = {Mario Ćurković and Nika Ćurković},
  journal = {Clinical case reports},
  year = {2026},
  month = oct,
  doi = {10.1002/ccr3.73718},
  url = {https://europepmc.org/article/PMC/PMC13673293},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Improvement of Erectile Function After Switching From Valsartan to Olmesartan Within a Fixed‐Dose Antihypertensive Combination: A Case Report
AU  - Mario Ćurković
AU  - Nika Ćurković
PY  - 2026
DA  - 2026/10/01
JO  - Clinical case reports
DO  - 10.1002/ccr3.73718
UR  - https://europepmc.org/article/PMC/PMC13673293
AB  - Intra‐class differences may exist between ARBs regarding tissue‐specific outcomes. In this case, valsartan was probably associated with erectile dysfunction (Naranjo score 7). Switching to olmesartan was followed by resolutions of symptoms. An intra‐class switch may be considered in selected patients with suspected drug‐associated erectile dysfunction after evaluating other vascular, metabolic, or lifestyle contributions. Clinicians should remain cautious, as concurrent treatment modifications can confound definitive causal attributions.
SN  - 2050-0904
ER  -